Breast Cancer
Conditions
Brief summary
Proportion of patients with undetectable MRD by ctDNA, who, after discontinuation of anti-HER2 therapy, remain free from mBC progression over a two-year follow-up period. Anti-HER2 therapy could be reintroduced upon molecular progression.
Interventions
DRUGPerjeta 420 mg concentrate for solution for infusion
Sponsors
Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients with undetectable MRD by ctDNA, who, after discontinuation of anti-HER2 therapy, remain free from mBC progression over a two-year follow-up period. Anti-HER2 therapy could be reintroduced upon molecular progression. | — |
Outcome results
None listed